Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

“…The number of participants in the control groups (including cancer and noncancer) evaluated in studies was 1607. Only 90 studies (35%) included a comparison group in the study design, with most comparison groups being subjects with cancer.…”

Section: Resultsmentioning

confidence: 99%

Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained?

et al. 2014

View full text Add to dashboard Cite

Although sleep is vital to all human functioning and poor sleep is a known problem in cancer, it is unclear whether the overall prevalence of the various types of sleep disorders in cancer is known. The purpose of this systematic literature review was to evaluate if the prevalence of sleep disorders could be ascertained from the current body of literature regarding sleep in cancer. This was a critical and systematic review of peer-reviewed, English-language, original articles published from 1980 through 15 October 2013, identified using electronic search engines, a set of key words, and prespecified inclusion and exclusion criteria. Information from 254 full-text, English-language articles was abstracted onto a paper checklist by one reviewer, with a second reviewer randomly verifying 50% (k = 99%). All abstracted data were entered into an electronic database, verified for accuracy, and analyzed using descriptive statistics and frequencies in SPSS (v.20) (North Castle, NY). Studies of sleep and cancer focus on specific types of symptoms of poor sleep, and there are no published prevalence studies that focus on underlying sleep disorders. Challenging the current paradigm of the way sleep is studied in cancer could produce better clinical screening tools for use in oncology clinics leading to better triaging of patients with sleep complaints to sleep specialists, and overall improvement in sleep quality.

show abstract

“…Pregabalin treated patients were shown to exhibit maximum improvement in terms of pain evaluation parameters (pain score and secondary outcome measures such as intensity of lancinating, dysesthesia and burning) along with clinically significant morphine sparing effect [45]. The post hoc analysis of pregabalin vs. non-pregabalin-treated cancer pain patients (n=273) in a 2-month prospective, multicentre study also reported that pregabalin treatment produces more satisfactory improvement to usual treatment (92.6% vs. 78.9%) in terms of decreased pain intensity, interference with normal daily activities and sleep quality [46]. …”

Section: Evidences From Clinical Studiesmentioning

confidence: 99%

Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms

Verma¹,

Singh²,

Jaggi

2014

154

126

View full text Add to dashboard Cite

Pregabalin is an antagonist of voltage gated Ca2+ channels and specifically binds to alpha-2-delta subunit to produce antiepileptic and analgesic actions. It successfully alleviates the symptoms of various types of neuropathic pain and presents itself as a first line therapeutic agent with remarkable safety and efficacy. Preclinical studies in various animal models of neuropathic pain have shown its effectiveness in treating the symptoms like allodynia and hyperalgesia. Clinical studies in different age groups and in different types of neuropathic pain (peripheral diabetic neuropathy, fibromyalgia, post-herpetic neuralgia, cancer chemotherapy-induced neuropathic pain) have projected it as the most effective agent either as monotherapy or in combined regimens in terms of cost effectiveness, tolerability and overall improvement in neuropathic pain states. Preclinical studies employing pregabalin in different neuropathic pain models have explored various molecular targets and the signaling systems including Ca2+ channel-mediated neurotransmitter release, activation of excitatory amino acid transporters (EAATs), potassium channels and inhibition of pathways involving inflammatory mediators. The present review summarizes the important aspects of pregabalin as analgesic in preclinical and clinical studies as well as focuses on the possible mechanisms.

show abstract

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Cited by 17 publications

References 46 publications

Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities

Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities

Systematic review of sleep disorders in cancer patients: can the prevalence of sleep disorders be ascertained?

Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms

Contact Info

Product

Resources

About